Tremor Clinical Trial
Official title:
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.
Status | Recruiting |
Enrollment | 165 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria: 1. Males and females of diverse racial and ethnic backgrounds; 2. Age 18-80 years; 3. Native English speakers; 4. Right-handed; 5. Normal cognitive status; 6. Patients will have laryngeal dystonia or voice tremor; 7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems. Exclusion criteria: 1. Subjects who are incapable of giving informed consent; 2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies; 3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis; 4. Patients with any other form of dystonia; 5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia; 6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation; 7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded; 8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded; 9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts Eye and Ear and University of Utah | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts Eye and Ear Infirmary | University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in voice symptoms | Clinical phenotypic features and speech structure kinematics that distinguish between laryngeal dystonia and voice tremor | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02427646 -
Kinematic-guided BoNT-A Treatment for ET and PD Tremor
|
Phase 2 | |
Completed |
NCT01018485 -
The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
|
Phase 3 | |
Completed |
NCT02087046 -
Deep Brain Stimulation (DBS) for the Suppression of Tremor
|
N/A | |
Recruiting |
NCT05413291 -
Natural History Protocol for Movement Disorders
|
||
Recruiting |
NCT04654429 -
Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients?
|
Phase 4 | |
Recruiting |
NCT04825119 -
Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen
|
||
Completed |
NCT05152836 -
The Effect of Vibrotactile Stimulation on Parkinson's Tremor
|
N/A | |
Recruiting |
NCT04071847 -
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
|
||
Completed |
NCT02046863 -
Pilot Study for Automated Deep Brain Stimulation Programming
|
N/A | |
Not yet recruiting |
NCT06378619 -
Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach
|
||
Completed |
NCT03300193 -
The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease
|
N/A | |
Completed |
NCT01932463 -
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor
|
N/A | |
Recruiting |
NCT05216770 -
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
|
Early Phase 1 | |
Not yet recruiting |
NCT06174948 -
The Use of the CUE1 in People With Parkinson's Disease and Related Disorders
|
N/A | |
Completed |
NCT01093027 -
Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
|
N/A | |
Completed |
NCT00001667 -
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
|
N/A | |
Completed |
NCT00001324 -
PET Scan to Study Brain Control of Human Movement
|
||
Completed |
NCT04299087 -
Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
|
N/A | |
Recruiting |
NCT05150093 -
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
|
N/A | |
Not yet recruiting |
NCT05456451 -
Effectiveness of Noninvasive Vagus Stimulation for Upper Extremity in Parkinson's Disease
|
N/A |